Skip to main content
. 2012 Jun 14;26(8):1316–1326. doi: 10.1210/me.2011-1180

Fig. 1.

Fig. 1.

Rimonabant exposure decreases yolk size use in a CB1-dependant manner. A, Embryos treated with 5 μm of rimonabant from 10 to 48 hpf display a bigger yolk sac (2, 4) compared with untreated wild type (1, 3). The red lines represent the maximum length of the yolk sac in wild types, whereas the yellow lines represent the maximum length of the head in wild types. Notes that rimonabant-treated embryos have a bigger yolk sac but have the same head size compared with wild type. B, 1, Wild-type embryos at 5 dpf with an average yolk sac size of 0.57 mm (2). Rimonabant-treated embryos, 1 μm from 10 hpf onward display a bigger yolk sac (3). Injection of CB1 morpholino abolishes the effect of rimonabant exposure, whereas injection of CB2 morpholino (4) does not. See Supplemental Fig. 2 for the efficacy of the CB1 morpholino. C, Rimonabant exposure from 5 to 72 hpf led to ca. 20% increase of the yolk sac size. This effect is blocked by CB1 morpholino injection but not by CB2 morpholino injection. D, Fat accumulation is decreased in rimonabant-treated embryos (middle panel) compared with the wild type (left panel). Note the decrease of Oil Red O staining in the telencephalon (arrowhead) and around the eye (arrow). Exposure to the CB1 agonist WIN 55,212-2 increases fat accumulation (right panel).